Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy

por Novotny, J. F., Cogswell, J., Inzunza, H., Harbison, C., Horak, C., Averbuch, S.
Publicado 2016

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer

por Baker, J B, Dutta, D, Watson, D, Maddala, T, Munneke, B M, Shak, S, Rowinsky, E K, Xu, L-A, Harbison, C T, Clark, E A, Mauro, D J, Khambata-Ford, S
Publicado 2011

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer

por Jonker, D J, Karapetis, C S, Harbison, C, O'Callaghan, C J, Tu, D, Simes, R J, Malone, D P, Langer, C, Tebbutt, N, Price, T J, Shapiro, J, Siu, L L, Wong, R P W, Bjarnason, G, Moore, M J, Zalcberg, J R, Khambata-Ford, S
Publicado 2014